COVID-19 vaccination in Japan

Last updated
COVID-19 vaccination in Japan
Japan map of fully vaccinated people by percentage of population by prefecture as of 23rd of June 2021.png
Japan map by prefecture. Percentage of people got fully vaccinated by population as of 9rd of January 2023. [1]
Date17 February 2021 (2021-02-17) – 13 April 2023 (2023-04-13)
LocationJapan
Cause COVID-19 pandemic in Japan
TargetFull immunisation of people in Japan against COVID-19
Organised by Ministry of Health, Labour and Welfare
Participants77,098,247 people have received at least one vaccine dose
(7 September 2021)
61,995,078 have been fully vaccinated (received both vaccine doses, 7 September 2021) [2] [3]
Outcome81.8% of the Japanese population has received their first dose of a two-dose vaccine
80.6% has been fully vaccinated
58.8% has received a booster shot
Website Ministry of Health, Labour and Welfare
Yoshihide Suga, the prime minister of Japan vaccinated with a COVID-19 vaccine COVID-19wakuchin(huaizaZhi )noJie Zhong woXing uJian Yi Wei Shou Xiang 4.jpg
Yoshihide Suga, the prime minister of Japan vaccinated with a COVID-19 vaccine

COVID-19 vaccination in Japan started later than in most other major economies. [4] The country has frequently been regarded as "slow" in its vaccination efforts. [5] [6]

Contents

Japan has so far approved Pfizer–BioNTech, Moderna and Oxford–AstraZeneca for use. In April 2024, data from the government shows that 79.5% of people have had their second dose, while 80.4% have received first shot. [7] Today, 79 percent of Japanese people have received two doses of a COVID-19 vaccine; 67 percent have received a third (booster) dose. [8]

Background

On 14 February 2021, Pfizer was approved by the government of Japan, [9] and was deployed on 17 February 2021. [10] On 28 May 2021, Pfizer was approved by the Japanese health ministry panel for adolescents aged between 12 and 15 years. [11]

On 21 May 2021, Moderna and Astrazeneca were approved by the government of Japan. [12]

Vaccines on order

VaccineApprovalDeploymentDoses secured
(million) [13]
Pfizer–BioNTech Green check.svg 14 February 2021Green check.svg 17 February 2021194
Moderna Green check.svg 21 May 2021 [12] Green check.svg 23 May 2021 [14] 100 [15] [16]
Oxford–AstraZeneca Green check.svg 21 May 2021 [12] Green check.svg 16 August 2021 [17] 120
Janssen Green check.svg 20 June 2022 [18] Dark Red x.svg No
Novavax Green check.svg 19 April 2022 [19] Green check.svg 26 May 2022150 [20]

Note: Japan has donated 1.24 million doses of AstraZeneca vaccine to Taiwan and 1 million doses to Vietnam. There are plans to send additional 2 million doses to these countries. Japan has also donated 1 million doses each to Thailand, Malaysia, Indonesia and the Philippines. [21]

Vaccines in trial stage

VaccineCountry of originType (technology)ProgressRef
AG0302-COVID‑19
AnGes Inc., AMED 		Japan DNA vaccine (plasmid)Phase II–III (500)
Randomized, double-blind, placebo controlled
Nov 2020 –Apr 2021, Japan		 [22] [23] [24] [25]
S-268019
Shionogi 		Japan Subunit Phase I–II (214)
Randomized, double-blind, placebo-controlled, parallel-group.
Dec 2020 –Jun 2022, Japan		 [26]
DS-5670
Daiichi Sankyo 		Japan RNA Phase I–II (152)
A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects.
Mar 2021 –Jul 2022, Japan		 [27] [28] [29]
KD-414
KM Biologics Co		Japan Inactivated SARS‑CoV‑2 Phase I–II (210)
Randomized, double blind, placebo control, parallel group.
Mar 2021 – Dec 2022, Japan		 [30] [31]
EXG-5003
Elixirgen Therapeutics, Fujita Health University 		Japan, United States RNA Phase I–II (60)
First in Human, randomized, placebo-controlled.
Apr 2021 –Jan 2023, Japan		 [32]

History

In April 2021, prime minister Suga Yoshihide announced that Japan will receive 50 million doses of the Pfizer vaccine after a meeting with the company's CEO. [4] [33]

The roll out of the vaccines in Japan, with 4 percent of the population inoculated as of May 21, 2021, has led to criticisms of slow approval, disruptions on import, and the lack of medical professionals. [34] [35] A poll conducted in April showed that more than 60 percent of people were dissatisfied with Japan's vaccine rollout, with experts stating that it was too late now to stop the spread of variants with vaccines. [36]

On May 21, 2021, several municipal governments in Kanagawa Prefecture were getting rid of their Moderna vaccine stocks as the doses are near their expiry date. [37] On June 5, 2022, around 740,000 Moderna doses will be disposed of due to being expired. [38]

Distribution issues

2020 Summer Olympics

Related Research Articles

<span class="mw-page-title-main">COVID-19 vaccination in Italy</span> Immunization plan against COVID-19 in Italy

The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.

<span class="mw-page-title-main">COVID-19 vaccination in Australia</span> Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all coerced people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, and were threatened with loss of jobs if they did not comply before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Canada</span> COVID-19 vaccination programme in Canada

COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020, and is currently ongoing.

COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Vietnam</span> Plan to immunize against COVID-19 in Vietnam

The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.

The COVID-19 vaccination campaign in Quebec was a provincial effort to distribute and administer vaccines against COVID-19.

<span class="mw-page-title-main">COVID-19 vaccination in South Korea</span> Plan to immunize against COVID-19

COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

<span class="mw-page-title-main">COVID-19 vaccination in Indonesia</span> Plan to immunize against COVID-19

The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.

The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.

<span class="mw-page-title-main">COVID-19 vaccination in Bangladesh</span> Immunisation programme against COVID-19 in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

COVID-19 vaccination in Iceland is an effort to immunize the adult population of Iceland due to the COVID-19 pandemic. As of July 2021, more than 260,000 individuals had received at least one dose of COVID-19 vaccine, which was over 78% of the country's population. On November 21, 2021, 90% of the target population had been fully vaccinated, while around 1 in 5 people had received a booster on top of that; by December 9, 2021, the share of the population having received a booster shot exceeded 50%. On December 13, 2021, the country began offering Pfizer vaccinations to children aged 5–11.

<span class="mw-page-title-main">COVID-19 vaccination in Sri Lanka</span> Plan to immunize against COVID-19

COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.

<span class="mw-page-title-main">COVID-19 vaccination in Taiwan</span> Plan to immunize against COVID-19

COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country.

The COVID-19 vaccination campaign began in Fiji on the first quarter of 2021 and will continue throughout the year with the goal of vaccinating all eligible Fijians. The government has made it mandatory for all eligible adults to take the COVID-19 vaccines.

<span class="mw-page-title-main">COVID-19 vaccine clinical research</span> Clinical research to establish the characteristics of COVID-19 vaccines

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

<span class="mw-page-title-main">KD-414</span> Vaccine candidate against COVID-19

KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.

COVID-19 vaccination in Ontario began in December 2020, when the first doses of the Pfizer-BioNTech COVID-19 vaccine were administered. In February 2021, shipments for both the Pfizer and Moderna vaccines increased significantly. By May 2021, over 50 percent of Ontarians had received their first dose. By the beginning of 2022, over 80 percent of Ontarians had received their first dose.

References

  1. ↑ Japan COVID-19 Vaccine Tracker: Prefectures Map Archived 2021-06-24 at the Wayback Machine . By George Karabassis Archived 2022-04-14 at the Wayback Machine . Click on the 1M and 2x buttons on the bottom right of the map to produce the map shown above.
  2. ↑ "Ongoing Topics - Novel Coronavirus Vaccines". Prime Minister of Japan and His Cabinet. 8 September 2021. Archived from the original on 2021-02-25. Retrieved 9 September 2021.
  3. ↑ "新型コロナワクチンについて". Archived from the original on 2021-12-23. Retrieved 2021-09-28.
  4. 1 2 Kanishka Singh (2021-04-18). "UPDATE 1-Japanese PM, Pfizer CEO discuss delivery of additional vaccine doses in 2021 to Japan". Archived from the original on 2021-07-06. Retrieved 2021-05-25.
  5. ↑ "Japan's slow vaccination process as Tokyo 2020 looms". CNN. April 26, 2021. Archived from the original on 2021-11-06. Retrieved 2021-05-25.
  6. ↑ Blake Essig, Emiko Jozuka and Ben Westcott (April 14, 2021). "With 100 days until the Tokyo Olympics, Japan has vaccinated less than 1% of its population. That's a problem". CNN. Archived from the original on 2021-11-05. Retrieved 2021-05-25.
  7. ↑ "新型コロナワクチンの接種回数について （令和６年４月１日公表）". www.mhlw.go.jp (in Japanese). Archived from the original on 2024-04-18. Retrieved 2024-04-18.
  8. ↑ cycles, This text provides general information Statista assumes no liability for the information given being complete or correct Due to varying update; Text, Statistics Can Display More up-to-Date Data Than Referenced in the. "Topic: Coronavirus (COVID-19) in Japan". Statista. Archived from the original on 2022-10-13. Retrieved 2022-10-13.
  9. ↑ "Japan approves Pfizer's COVID-19 vaccine, 1st for domestic use". Nikkei Asia . 14 February 2021. Archived from the original on 18 March 2021. Retrieved 14 February 2021.
  10. ↑ "Japan gives first COVID-19 vaccinations to Tokyo health workers". The Japan Times. 17 February 2021. Archived from the original on 14 August 2021. Retrieved 31 May 2021.
  11. ↑ "Japan to approve Pfizer COVID-19 vaccine for 12- to 15-year-olds". Kyodo News. 28 May 2021. Archived from the original on 3 June 2021. Retrieved 31 May 2021.
  12. 1 2 3 "Japan issues final approval for Moderna and AstraZeneca vaccines". The Japan Times. 2021-05-21. Archived from the original on 2021-05-21.
  13. ↑ "Japan gives preliminary OK to 2 more COVID-19 vaccines". Associated Press. May 20, 2021.
  14. ↑ "自衛隊員にモデルナ製ワクチン 国内初、大規模接種会場を運営". Tokyo Shimbun. 23 May 2021. Archived from the original on 2 June 2021. Retrieved 2 June 2021.
  15. ↑ "新型コロナウイルスワクチンの供給に係るモデルナ社及び武田薬品工業株式会社との契約締結について" (PDF). Ministry of Health, Labour and Welfare. October 29, 2020. Archived (PDF) from the original on July 7, 2021. Retrieved September 9, 2021.
  16. ↑ "新型コロナウイルスワクチンの来年に向けた供給に係る武田薬品工業株式会社及びモデルナ社との契約締結について". Ministry of Health, Labour and Welfare. July 20, 2021. Archived from the original on August 26, 2021. Retrieved September 9, 2021.
  17. ↑ "Japan begins using AstraZeneca vaccine in bid to step up inoculations". The Japan Times. 23 August 2021. Archived from the original on 18 November 2021. Retrieved 23 August 2021.
  18. ↑ "J＆Jワクチンを国内で承認 5種類目、接種は自己負担". Kyodo News. 20 June 2022. Archived from the original on 26 June 2022. Retrieved 26 June 2022.
  19. ↑ "Japan greenlights Novavax vaccine, shots to start as early as May". Mainichi Shimbun. 19 April 2022. Archived from the original on 18 April 2022. Retrieved 19 April 2022.
  20. ↑ "来年の新型コロナワクチンの供給に係る武田薬品工業株式会社との契約締結について". Ministry of Health, Labour and Welfare. September 7, 2021. Archived from the original on September 7, 2021. Retrieved September 9, 2021.
  21. ↑ "Japan to give 6 mln doses of vaccines to Taiwan, 5 SE Asia nations". Reuters. June 25, 2021. Archived from the original on 2021-06-25. Retrieved 2021-07-02.
  22. ↑ "About AnGes – Introduction". AnGes, Inc. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  23. ↑ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov . United States National Library of Medicine. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  24. ↑ "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 10 April 2021. Retrieved 11 March 2021.
  25. ↑ "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 3 May 2021. Retrieved 11 March 2021.
  26. ↑ "Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults". jrct.niph.go.jp. Japan Registry of Clinical Trials. Archived from the original on 7 July 2021. Retrieved 21 March 2021.
  27. ↑ "Daiichi Sankyo Initiates Phase 1/2 Clinical Trial for mRNA COVID-19 vaccine in Japan" (PDF) (Press release). Daiichi Sankyo. Archived (PDF) from the original on 13 April 2021. Retrieved 17 April 2021.
  28. ↑ "Daiichi takes mRNA COVID-19 vaccine into clinic as Japanese R&D belatedly fires up". Fierce Biotech. March 22, 2021. Archived from the original on 12 April 2021. Retrieved 12 April 2021.
  29. ↑ "Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 9 October 2021. Retrieved 12 April 2021.
  30. ↑ "Japan's KM Biologics begins clinical trial of COVID-19 vaccine candidate". Reuters. 22 March 2021. Archived from the original on 13 April 2021. Retrieved 31 May 2021.
  31. ↑ "20歳以上65歳未満の健康成人、及び65歳以上の健康な高齢者を対象に、COVID-19に対するワクチン（KD-414）の安全性及び免疫原性を検討するための、プラセボを対照とする多施設共同二重盲検ランダム化並行群間比較試験". jrct.niph.go.jp. Japan Registry of Clinical Trials. Archived from the original on 1 May 2021. Retrieved 7 May 2021.
  32. ↑ "Safety and Immunogenicity of EXG-5003". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 9 October 2021. Retrieved 2 May 2021.
  33. ↑ "Japan to receive 50 mil. additional doses of Pfizer vaccine". April 21, 2021. Archived from the original on 2021-05-25. Retrieved 2021-05-25.
  34. ↑ Kosaka, Makoto; Hashimoto, Takanao; Ozaki, Akihiko; Tanimoto, Tetsuya; Kami, Masahiro (2021-06-02). "Delayed COVID-19 vaccine roll-out in Japan". The Lancet. 397 (10292): 2334–2335. doi:10.1016/S0140-6736(21)01220-4. ISSN   0140-6736. PMC   8172150 . PMID   34089658.
  35. ↑ "EXPLAINER: Why Japan has been slow to roll out vaccinations". The Asahi Shimbun. Archived from the original on 2021-06-08. Retrieved 2021-06-08.
  36. ↑ McCurry, Justin (26 April 2021). "Japan's slow Covid vaccine rollout casts cloud over Olympics". The Guardian . Archived from the original on 2021-04-26. Retrieved 8 June 2021.
  37. ↑ "Japan local gov'ts to dump large stocks of almost expired Moderna COVID vaccine". Mainichi Daily News. 21 May 2022. Archived from the original on 23 May 2022. Retrieved 23 May 2022.
  38. ↑ "740,000 Moderna doses scrapped due to expiration in 27 Japan cities". Mainichi Daily News. 5 June 2022. Archived from the original on 10 June 2022. Retrieved 10 June 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.